This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.


Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


4mbk

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (11:07, 21 December 2022) (edit) (undo)
 
(4 intermediate revisions not shown.)
Line 1: Line 1:
-
'''Unreleased structure'''
 
-
The entry 4mbk is ON HOLD until Paper Publication
+
==Crystal structure of K234R inhibitor-resistant variant of SHV beta-lactamase in complex with SA2-13==
 +
<StructureSection load='4mbk' size='340' side='right'caption='[[4mbk]], [[Resolution|resolution]] 1.46&Aring;' scene=''>
 +
== Structural highlights ==
 +
<table><tr><td colspan='2'>[[4mbk]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Klebsiella_pneumoniae Klebsiella pneumoniae]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4MBK OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4MBK FirstGlance]. <br>
 +
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=MA4:CYCLOHEXYL-HEXYL-BETA-D-MALTOSIDE'>MA4</scene>, <scene name='pdbligand=SA2:(3R)-4-[(4-CARBOXYBUTANOYL)OXY]-N-[(1E)-3-OXOPROP-1-EN-1-YL]-3-SULFINO-D-VALINE'>SA2</scene></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4mbk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4mbk OCA], [https://pdbe.org/4mbk PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4mbk RCSB], [https://www.ebi.ac.uk/pdbsum/4mbk PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4mbk ProSAT]</span></td></tr>
 +
</table>
 +
== Function ==
 +
[https://www.uniprot.org/uniprot/BLA1_KLEPN BLA1_KLEPN]
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
beta-Lactamases are the major reason beta-lactam resistance is seen in Gram-negative bacteria. To combat this resistance mechanism, beta-lactamase inhibitors are currently being developed. Presently, there are only three that are in clinical use (clavulanate, sulbactam and tazobactam). In order to address this important medical need, we explored a new inhibition strategy that takes advantage of a long-lived inhibitory trans-enamine intermediate. SA2-13 was previously synthesized and shown to have a lower k(react) than tazobactam. We investigated here the importance of the carboxyl linker length and composition by synthesizing three analogs of SA2-13 (PSR-4-157, PSR-4-155, and PSR-3-226). All SA2-13 analogs yielded higher turnover numbers and k(react) compared to SA2-13. We next demonstrated using protein crystallography that increasing the linker length by one carbon allowed for better capture of a trans-enamine intermediate; in contrast, this trans-enamine intermediate did not occur when the C2 linker length was decreased by one carbon. If the linker was altered by both shortening it and changing the carboxyl moiety into a neutral amide moiety, the stable trans-enamine intermediate in wt SHV-1 did not form; this intermediate could only be observed when a deacylation deficient E166A variant was studied. We subsequently studied SA2-13 against a relatively recently discovered inhibitor-resistant (IR) variant of SHV-1, SHV K234R. Despite the alteration in the mechanism of resistance due to the K--&gt;R change in this variant, SA2-13 was effective at inhibiting this IR enzyme and formed a trans-enamine inhibitory intermediate similar to the intermediate seen in the wt SHV-1 structure. Taken together, our data reveals that the C2 side chain linker length and composition profoundly affect the formation of the trans-enamine intermediate of penam sulfones. We also show that the design of SA2-13 derivatives offers promise against IR SHV beta-lactamases that possess the K234R substitution.
-
Authors: Rodkey, E.A., van den Akker, F.
+
Penam sulfones and beta-lactamase inhibition: SA2-13 and the importance of the C2 side chain length and composition.,Rodkey EA, Winkler ML, Bethel CR, Pagadala SR, Buynak JD, Bonomo RA, van den Akker F PLoS One. 2014 Jan 16;9(1):e85892. doi: 10.1371/journal.pone.0085892. eCollection, 2014. PMID:24454944<ref>PMID:24454944</ref>
-
Description: Crystal structure of K234R inhibitor-resistant variant of SHV beta-lactamase in complex with SA2-13
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
<div class="pdbe-citations 4mbk" style="background-color:#fffaf0;"></div>
 +
 
 +
==See Also==
 +
*[[Beta-lactamase 3D structures|Beta-lactamase 3D structures]]
 +
== References ==
 +
<references/>
 +
__TOC__
 +
</StructureSection>
 +
[[Category: Klebsiella pneumoniae]]
 +
[[Category: Large Structures]]
 +
[[Category: Rodkey EA]]
 +
[[Category: Van den Akker F]]

Current revision

Crystal structure of K234R inhibitor-resistant variant of SHV beta-lactamase in complex with SA2-13

PDB ID 4mbk

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools